Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd (ZTEK) delivers cutting-edge innovations in healthcare technology and advanced materials through its patented intellectual property portfolio. This news hub provides investors and industry observers with timely updates on corporate developments, regulatory milestones, and commercial partnerships.
Access verified press releases and analysis covering ZenGUARD™ antimicrobial advancements, battery material research, and strategic collaborations with academic institutions. Our curated feed ensures transparent tracking of financial announcements, product launches, and intellectual property expansions.
Key updates include earnings reports, technology licensing agreements, and progress in graphite purification techniques for energy storage applications. Bookmark this page to monitor Zentek's progress in enhancing medical safety standards and sustainable material solutions.
Zentek (NASDAQ:ZTEK) has signed a Memorandum of Understanding with Al-Ramez International Group through Saudi Excellence Holding Company to establish a strategic partnership in Saudi Arabia and the MENA region. The collaboration aims to develop a graphene production facility focusing on ZenGUARD™ technologies and create a commercialization hub for Zentek's technologies.
The partnership encompasses multiple objectives, including advancing Triera Biosciences' aptamer technology, developing the Albany Graphite Deposit, and establishing research facilities in conjunction with Saudi universities. Additionally, Zentek has been accepted into the World Trade Centre Toronto's Trade Accelerator Program to support its international expansion efforts.
Zentek has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on December 3, 2024, confirming that it has met the listing rule 5550(a)(2), which requires securities to maintain a minimum bid price of US$1.00 per share. Zentek's common stock has traded above the US$1.00 threshold for 11 consecutive business days, satisfying the requirement.
Zentek (NASDAQ:ZTEK) announces plans to add ZenGUARD™ Enhanced Air Filters under its existing medical device establishment licence (MDEL). Independent testing showed the filters achieve ~66% viral filtration efficiency enhancement compared to untreated filters, maintaining ~67% VFE over 6 months with minimal pressure drop changes. A ParticleOne study demonstrated the product's effectiveness in reducing viral pathogens and potential cost savings from reduced absenteeism. The company will need additional testing and documentation to qualify the filters as a medical device under MDEL and ISO 13485:2016 compliance. Additionally, Nick Hansford, VP of Strategy and Product Development, has departed the company.
Zentek and its subsidiary Triera Biosciences have secured a $1.1 million contract from the Government of Canada to test their multivalent aptamer technology for rapid drug discovery targeting highly pathogenic avian influenza (HPAI) A(H5N1). The project involves collaboration with Health Emergency Readiness Canada (HERC) and Defence Research and Development Canada (DRDC). Triera must develop a lead candidate within six months, which will be tested for therapeutic and prophylactic efficacy at McMaster University. The company has previously demonstrated success with this platform by developing a universal therapeutic effective against all SARS-CoV-2 variants.
Zentek (NASDAQ:ZTEK) has withdrawn its submission to Health Canada's Pest Management Regulatory Agency (PMRA) for ZenGUARD™ Enhanced Air Filters. Based on PMRA feedback and analysis of the Canadian regulatory environment, the company will pursue alternative, more cost-effective and timely pathways to bring the product to market in Canada. The company had been evaluating these alternative options while awaiting PMRA assessment. ZenGUARD™ filters are designed to control infectious aerosols without significantly increasing energy consumption and emissions in buildings.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) has provided an update on the commercialization of its ZenGUARD™ Antimicrobial Surgical Masks. Following a Canada-wide sampling program for dental professionals through Henry Schein Inc., the company is experiencing increased demand for its product. Zentek is exploring opportunities in the beauty space and international healthcare markets. The company has applied to the FDA for authorization to sell ZenGUARD™ Surgical Masks in the United States and is currently evaluating additional information requests from the FDA.
CEO Greg Fenton highlighted that ZenGUARD™ masks not only provide better protection against infectious agents but also eliminate 99.9% of bacteria that can cause acne when wearing masks for extended periods. This unique value proposition is expected to drive demand in the dental market and potentially in the beauty industry.
Zentek (NASDAQ: ZTEK) (TSXV: ZEN) held its annual and special meeting of shareholders on September 26, 2024. Shareholders voted in favor of all resolutions presented. The meeting included the election of directors, with all nominees listed in the Management Information Circular being elected. Voting results for directors ranged from 81.258% to 98.899% in favor.
Shareholders also approved the appointment of BDO Canada LLP as the Company's auditors with 99.275% of votes in favor. Additionally, the Company's omnibus long-term incentive plan was approved and confirmed with 82.077% of votes in favor and 17.923% against.
The Management Information Circular, dated August 19, 2024, containing details of all resolutions, is available on the Company's SEDAR+ profile.
Zentek (NASDAQ: ZTEK) (TSXV: ZEN) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's shares have traded below $1.00 for 31 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Zentek has until March 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Failure to meet requirements could result in delisting, though Zentek can appeal such a decision. The company's management is actively monitoring the situation and considering options to address the deficiency.
Zentek (Nasdaq:ZTEK, TSXV:ZEN) has announced plans for a normal course issuer bid, subject to regulatory approval. The company aims to repurchase up to 5,084,319 common shares, representing approximately 5% of its outstanding shares, over a one-year period from August 16, 2024, to August 15, 2025. Zentek can purchase up to 2,033,727 shares (2% of outstanding shares) in any 30-day period during the bid.
Management believes this strategy will increase long-term shareholder value, as the current market price may not fully reflect the company's business value and future prospects. Purchases will be made through the TSX Venture Exchange at market prices, with Integral Wealth Securities appointed as the broker for these transactions.
Zentek (Nasdaq:ZTEK)(TSX-V:ZEN) has announced preliminary battery results and a new three-year, $441,000 project in collaboration with the University of Toronto. The project, funded by an NSERC Mission Alliance Grant, aims to optimize graphite for battery anode use. Key highlights include:
1. Preliminary results show a minimum 17% increase in capacity for pouch cell batteries using engineered Albany graphite compared to commercial-grade anode material.
2. This project complements a $1.6M Mitacs research project announced in October 2022, focusing on multifunctional materials for automotive batteries.
3. Zentek is exploring both graphite production from its Albany Deposit and graphite processing for battery-ready anode material.
The company aims to develop premium anode materials that outperform commercial anodes in energy capacity, cycle life, and charging rate.
